{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:13:58Z","timestamp":1792502038269,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01 DA048172"],"award-info":[{"award-number":["K01 DA048172"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30 DA030500"],"award-info":[{"award-number":["P30 DA030500"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000905","name":"the Commonwealth Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000905","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Global study data show injection drug use is driving upwards of 79% of all new hepatitis C virus (HCV) cases in high-income countries. Low-threshold models can engage vulnerable populations in treatment to achieve HCV elimination targets. We examined the implementation of low-threshold models for HCV care in New York State, which has a robust HCV elimination program.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted semi-structured interviews with 16 healthcare providers in 2022. Included providers either self-described as \u201clow-threshold,\u201d had a clinical focus on marginalized populations, or practiced in non-traditional settings. Interviews focused on the implementation of low-threshold HCV care. Transcripts were analyzed using thematic analysis and were categorized into themes guided by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Providers implemented low-threshold HCV care by facilitating access (e.g., having walk-in or telemedicine HCV services). Point-of-care testing and peer support were other important features. The inner context was driven by provider and organization values and involved providing low-threshold HCV care within health systems that were not themselves \u201clow-threshold.\u201d Adequate staffing was crucial for the extensive care coordination and outreach activities needed to engage persons who inject drugs (PWID). The outer context was characterized by a limited funding environment, restrictive insurance policies, and the high impact of patients' unmet social needs. Providers relied on care coordination and integrated care models to overcome these barriers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Low-threshold HCV care incorporates operational flexibility and patient navigation but is challenged by patients' unmet social needs. Jurisdictions can support implementation by providing adequate funding for substantial outreach activities needed to engage vulnerable populations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf184","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T16:42:47Z","timestamp":1743266567000},"source":"Crossref","is-referenced-by-count":3,"title":["Providers\u2019 Perspectives on Implementation of Low-threshold HCV Treatment in New York State: A Qualitative Study"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2705-8010","authenticated-orcid":false,"given":"Ane-Kristine","family":"Finbr\u00e5ten","sequence":"first","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medicine , New York New York ,","place":["USA"]},{"name":"Harkness Fellowship in Healthcare Policy and Practice, Commonwealth Fund , New York New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina L","family":"Chin","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medicine , New York New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7781-100X","authenticated-orcid":false,"given":"Meenakshi","family":"Seetharaman","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medicine , New York New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Hutchings","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medicine , New York New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2846-9762","authenticated-orcid":false,"given":"Benjamin J","family":"Eckhardt","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, New York University School of Medicine , New York New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1132-2932","authenticated-orcid":false,"given":"Bruce R","family":"Schackman","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medicine , New York New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6363-2839","authenticated-orcid":false,"given":"Shashi N","family":"Kapadia","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medicine , New York New York ,","place":["USA"]},{"name":"Division of Infectious Diseases, Weill Cornell Medicine , New York New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"2025052712081604600_ofaf184-B1","author":"Centers for Disease Control and Prevention"},{"key":"2025052712081604600_ofaf184-B2","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S1473-3099(16)30325-5","article-title":"Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013","volume":"16","author":"Degenhardt","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2025052712081604600_ofaf184-B3","volume-title":"Global health sector strategy on viral hepatitis 2016\u20132021","author":"World Health Organization","year":"2016"},{"key":"2025052712081604600_ofaf184-B4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s12325-020-01535-3","article-title":"Estimating the year each state in the United States will achieve the World Health Organization\u2019s elimination targets for hepatitis C","volume":"38","author":"Sulkowski","year":"2021","journal-title":"Adv Ther"},{"key":"2025052712081604600_ofaf184-B5","author":"New York State Department of Health"},{"key":"2025052712081604600_ofaf184-B6","author":"New York City Department of Health and Mental Hygiene"},{"key":"2025052712081604600_ofaf184-B7","author":"Hep Free NYC"},{"key":"2025052712081604600_ofaf184-B8","author":"New York State Department of Health"},{"key":"2025052712081604600_ofaf184-B9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","article-title":"Defining low-threshold buprenorphine treatment","volume":"14","author":"Jakubowski","year":"2020","journal-title":"J Addict Med"},{"key":"2025052712081604600_ofaf184-B10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12954-023-00831-9","article-title":"\u201cTreated like a human being\u201d: perspectives of people who inject drugs attending low-threshold HCV treatment at a syringe service program in New York City","volume":"20","author":"Kapadia","year":"2023","journal-title":"Harm Reduct J"},{"key":"2025052712081604600_ofaf184-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.12.021","article-title":"Opioid substitution therapy: lowering the treatment thresholds","volume":"161","author":"Kourounis","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"2025052712081604600_ofaf184-B12","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/liv.15266","article-title":"Peer support in small towns: a decentralized mobile hepatitis C virus clinic for people who inject drugs","volume":"42","author":"Midgard","year":"2022","journal-title":"Liver Int"},{"key":"2025052712081604600_ofaf184-B13","doi-asserted-by":"crossref","first-page":"114523","DOI":"10.1016\/j.socscimed.2021.114523","article-title":"Sample sizes for saturation in qualitative research: a systematic review of empirical tests","volume":"292","author":"Hennink","year":"2022","journal-title":"Soc Sci Med"},{"key":"2025052712081604600_ofaf184-B14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qual Health Res"},{"key":"2025052712081604600_ofaf184-B15","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1001\/jamainternmed.2022.0170","article-title":"Accessible hepatitis C care for people who inject drugs: a randomized clinical trial","volume":"182","author":"Eckhardt","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2025052712081604600_ofaf184-B16","doi-asserted-by":"crossref","first-page":"109265","DOI":"10.1016\/j.drugalcdep.2022.109265","article-title":"Cost of hepatitis C care facilitation for HIV\/hepatitis C co-infected people who use drugs","volume":"232","author":"Gutkind","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"2025052712081604600_ofaf184-B17","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1007\/s11606-020-06409-6","article-title":"A harm reduction approach to treating opioid use disorder in an independent primary care practice: a qualitative study","volume":"36","author":"Kapadia","year":"2021","journal-title":"J Gen Intern Med"},{"key":"2025052712081604600_ofaf184-B18","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/cid\/ciad711","article-title":"Opportunistic treatment of hepatitis C infection among hospitalized people who inject drugs (OPPORTUNI-C): a stepped wedge cluster randomized trial","volume":"78","author":"Midgard","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025052712081604600_ofaf184-B19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s10488-010-0327-7","article-title":"Advancing a conceptual model of evidence-based practice implementation in public service sectors","volume":"38","author":"Aarons","year":"2011","journal-title":"Adm Policy Ment Health"},{"key":"2025052712081604600_ofaf184-B20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s43058-020-00023-7","article-title":"Ten recommendations for using implementation frameworks in research and practice","volume":"1","author":"Moullin","year":"2020","journal-title":"Implement Sci Commun"},{"key":"2025052712081604600_ofaf184-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13012-018-0842-6","article-title":"Systematic review of the Exploration, Preparation, Implementation, Sustainment (EPIS) framework","volume":"14","author":"Moullin","year":"2019","journal-title":"Implement Sci"},{"key":"2025052712081604600_ofaf184-B22","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1007\/s11606-024-08807-6","article-title":"The state of hepatitis C elimination from the front lines: a qualitative study of provider-perceived gaps to treatment initiation","volume":"39","author":"Gonzalez","year":"2024","journal-title":"J Gen Intern Med"},{"key":"2025052712081604600_ofaf184-B23","doi-asserted-by":"crossref","first-page":"102138","DOI":"10.1016\/j.pmedr.2023.102138","article-title":"Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States","volume":"32","author":"Park","year":"2023","journal-title":"Prev Med Rep"},{"key":"2025052712081604600_ofaf184-B24","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s10620-017-4608-9","article-title":"Primary care and hepatology provider-perceived barriers to and facilitators of hepatitis C treatment candidacy and adherence","volume":"62","author":"Rogal","year":"2017","journal-title":"Dig Dis Sci"},{"key":"2025052712081604600_ofaf184-B25","doi-asserted-by":"crossref","first-page":"103917","DOI":"10.1016\/j.drugpo.2022.103917","article-title":"Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: a systematic review and meta-analysis","volume":"111","author":"Cunningham","year":"2023","journal-title":"Int J Drug Policy"},{"key":"2025052712081604600_ofaf184-B26","doi-asserted-by":"crossref","first-page":"e53049","DOI":"10.2196\/53049","article-title":"Care integration for hepatitis C virus treatment through facilitated telemedicine within opioid treatment programs: qualitative study","volume":"26","author":"Dickerson","year":"2024","journal-title":"J Med Internet Res"},{"key":"2025052712081604600_ofaf184-B27","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/jvh.14010","article-title":"United States provider experiences with telemedicine for hepatitis C treatment: a nationwide survey","volume":"31","author":"Patel","year":"2024","journal-title":"J Viral Hepat"},{"key":"2025052712081604600_ofaf184-B28","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jama.2024.2452","article-title":"Integrated hepatitis C-opioid use disorder care through facilitated telemedicine: a randomized trial","volume":"331","author":"Talal","year":"2024","journal-title":"JAMA"},{"key":"2025052712081604600_ofaf184-B29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S2468-1253(22)00346-6","article-title":"Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis","volume":"8","author":"Trickey","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025052712081604600_ofaf184-B30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11904-018-0390-3","article-title":"The syndemic of opioid misuse, overdose, HCV, and HIV: structural-level causes and interventions","volume":"15","author":"Perlman","year":"2018","journal-title":"Curr HIV\/AIDS Rep"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf184\/62748640\/ofaf184.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/4\/ofaf184\/62748640\/ofaf184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/4\/ofaf184\/62748640\/ofaf184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:08:48Z","timestamp":1748362128000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf184\/8096413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf184","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,26]]},"article-number":"ofaf184"}}